Invus Global Management, LLC - 29 Jan 2026 SCHEDULE 13D/A Report for Lexicon Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (LXRX)

Filing manager
Invus Global Management, LLC
Reporting owner
Artal Participations S.a r.l.
Security
Lexicon Pharmaceuticals, Inc. Common Stock, par value $0.001 per share
Beneficially owned shares
154,734,327 shares
Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13D/A

Active or control-oriented beneficial ownership filing.

Ownership

36%

Beneficial ownership of this reported class.

Shares

154,734,327 shares

Shares beneficially owned as disclosed.

Event date

29 Jan 2026

Date tied to the ownership event or amendment.

Accepted by SEC

02 Feb 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership
36%
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
LXRX
Shares outstanding
427,442,892 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13D/A
Accepted by SEC
02 Feb 2026, 21:54:05 UTC
Event date
29 Jan 2026
Next SEC filing
08 May 2026
Source filing
View source filing

Key filing fact

Invus Global Management, LLC disclosed 36% ownership in Lexicon Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (LXRX) on 29 Jan 2026.

Key facts

  • Invus Global Management, LLC filed SCHEDULE 13D/A for Lexicon Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (LXRX).
  • Disclosed ownership: 36%.
  • Date of event: 29 Jan 2026.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 02 Feb 2026, 21:54.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (18)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Invus, L.P. 10% 42,765,057 35,402,689 7,362,368 /s/ Raymond Debbane Raymond Debbane, President of Invus Advisors L.L.C., its general partner 0001404570
Invus Advisors, L.L.C. 10% 42,765,057 35,402,689 7,362,368 /s/ Raymond Debbane Raymond Debbane, President
Invus Public Equities, L.P. 1.7% 7,362,368 0 7,362,368 /s/ Raymond Debbane Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner
Invus Public Equities Advisors, LLC 1.7% 7,362,368 0 7,362,368 /s/ Raymond Debbane Raymond Debbane, President
Invus Global Management, LLC 10% 42,765,057 42,765,057 0 /s/ Raymond Debbane Raymond Debbane, President 0002005369
Siren, L.L.C. 10% 42,765,057 42,765,057 0 /s/ Raymond Debbane Raymond Debbane, President
Avicenna Life Sci Master Fund LP 0.4% 1,538,462 1,538,462 0 /s/ Raymond Debbane Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner
Avicenna Life Sci Master GP LLC 0.4% 1,538,462 1,538,462 0 /s/ Raymond Debbane Raymond Debbane, Chief Executive Officer
Invus US Partners LLC 1.3% 5,451,204 5,451,204 0 /s/ Raymond Debbane Raymond Debbane, President
Ulys, L.L.C. 1.6% 6,989,666 6,989,666 0 /s/ Raymond Debbane Raymond Debbane, President 0001218180
Mr. Raymond Debbane 12% 51,217,900 51,217,900 0 /s/ Raymond Debbane Raymond Debbane
Artal Participations S.a r.l. 36% 154,734,327 154,734,327 0 /s/ Pierre Claudel Pierre Claudel, Manager
Artal International S.C.A. 36% 154,734,327 154,734,327 0 /s/ Anne Goffard Anne Goffard, Managing Director of Artal International Management S.A., its managing partner
Artal International Management S.A. 36% 154,734,327 154,734,327 0 /s/ Anne Goffard Anne Goffard, Managing Director
Artal Group S.A. 36% 154,734,327 154,734,327 0 /s/ Anne Goffard Anne Goffard, Authorized Person
Westend S.A. 36% 154,734,327 154,734,327 0 /s/ Anne Goffard Anne Goffard, Managing Director
Stichting Administratiekantoor Westend 36% 154,734,327 154,734,327 0 /s/ Amaury Wittouck Amaury Wittouck, Sole Member of the Board
Mr. Amaury Wittouck 36% 154,734,327 154,734,327 0 /s/ Amaury Wittouck Amaury Wittouck
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .